Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

900
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
900
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.0K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ocular blood flow and retinal oxygen saturation measurements in central retinal artery occlusion.

Acta ophthalmologica·2026
Same author

The effect of rhegmatogenous retinal detachment on retinal oxygenation.

Acta ophthalmologica·2026
Same author

Chitosan-coated cyclodextrin-based niosomes enable enhanced nose-to-brain delivery of rivastigmine and asiaticoside for Alzheimer's disease.

International journal of biological macromolecules·2026
Same author

Retinal oxygen metabolism and ocular blood flow in patients with diabetic retinopathy of varying severity.

Acta ophthalmologica·2026
Same author

Referral for glaucoma surgery and types of surgery in different European regions in 2025, the EURACCUR study.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026
Same author

Impact of mono- or multitherapy on ocular surface health and quality of life after 5 years of follow-up in the Glaucoma Intensive Treatment Study (GITS).

Acta ophthalmologica·2026

Related Experiment Video

Updated: Dec 28, 2025

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.1K

Can postoperative dexamethasone nanoparticle eye drops replace mitomycin C in trabeculectomy?

Gauti Jóhannesson1,2,3, María Soffía Gottfredsdóttir3, Guðrún Marta Ásgrimsdóttir4

  • 1Department of Clinical Sciences, Ophthalmology, Umeå University, Umeå, Sweden.

Acta Ophthalmologica
|February 19, 2020
PubMed
Summary

Dexamethasone nanoparticle (DexNP) eye drops show effectiveness comparable to mitomycin C (MMC) after trabeculectomy surgery for glaucoma. This study suggests DexNP may serve as a viable alternative to MMC in glaucoma treatment.

Keywords:
dexamethasonedrug deliveryglaucomamitomycin Cnanoparticlestrabeculectomy

More Related Videos

Author Spotlight: Exploring Corneal Innate Immunity and Delayed Wound Healing in Diabetic Patients
03:57

Author Spotlight: Exploring Corneal Innate Immunity and Delayed Wound Healing in Diabetic Patients

Published on: January 10, 2025

20.4K
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.4K

Related Experiment Videos

Last Updated: Dec 28, 2025

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

33.1K
Author Spotlight: Exploring Corneal Innate Immunity and Delayed Wound Healing in Diabetic Patients
03:57

Author Spotlight: Exploring Corneal Innate Immunity and Delayed Wound Healing in Diabetic Patients

Published on: January 10, 2025

20.4K
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.4K

Area of Science:

  • Ophthalmology
  • Glaucoma Research
  • Surgical Interventions

Background:

  • Glaucoma management often requires surgical intervention like trabeculectomy to reduce intraocular pressure (IOP).
  • Postoperative care typically involves anti-inflammatory and antifibrotic agents to ensure surgical success and prevent complications.
  • Mitomycin C (MMC) is a commonly used antifibrotic agent, but alternatives are sought to minimize potential side effects.

Purpose of the Study:

  • To compare the efficacy and safety of 1.5% dexamethasone nanoparticle (DexNP) eye drops versus mitomycin C (MMC) with Maxidex® eye drops as postoperative treatments following trabeculectomy.
  • To evaluate intraocular pressure (IOP) reduction, success rates, and need for reoperations in patients undergoing primary trabeculectomy.

Main Methods:

  • A randomized prospective single-masked clinical trial involving 20 patients with primary open-angle glaucoma undergoing primary trabeculectomy.
  • Patients were divided into two groups: one receiving DexNP eye drops postoperatively (without intraoperative MMC) and a control group receiving MMC intraoperatively and Maxidex® eye drops postoperatively.
  • Outcomes including complete success (target IOP without medication or reoperation), relative success, medication use, and reoperations were assessed over 36 months.

Main Results:

  • Both treatment groups demonstrated similar postoperative courses and IOP reduction.
  • Mean IOPs were reduced from baseline levels (25.6 mmHg DexNP, 24.4 mmHg control) to 11.7-12.1 mmHg by 36 months in both groups.
  • No statistically significant differences were observed between the groups in absolute or relative success rates, number of medications, or reoperations at any time point.

Conclusions:

  • 1.5% dexamethasone nanoparticle (DexNP) eye drops are an effective postoperative treatment following trabeculectomy.
  • The potent anti-inflammatory and antifibrotic properties of DexNP suggest it could be a valuable alternative to mitomycin C in glaucoma surgery.
  • DexNP offers a promising option for managing postoperative inflammation and fibrosis after trabeculectomy, potentially improving patient outcomes.